Drug Trial Radar · NCT07643272
A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jun 30, 2026
Primary completion
Jul 31, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Jun 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, randomized, four-period, six-sequence study with a planned enrollment of 24 healthy participants. The study consists of a screening period, a dosing period (Cycles 1, 2, 3, and 4), and a follow-up period. Screening must occur within 14 days prior to the first dose of study drug. Enrolled participants will be randomly assigned to one of 6 dosing sequences in the ratio of 1:1:1:1:1:1 to complete Cycles 1-3 dosing to evaluate the effect of different types of food on the PK of HMPL-760, and then to receive rabeprazole and HMPL-760 in Cycle 4 to assess the effect of PPI on the PK of HMPL-760 (see dosing sequence table for details).
Conditions
- Healthy Participants
Interventions
HMPL-760Drug
300 mg HMPL-760 will be administered orally once daily on Day 1, Day 6 and Day 11.
Rabeprazole and HMPL-760Drug
20 mg of rabeprazole will be administered orally once daily in the morning from Day 15 to Day 21, and a 300 mg oral dose of HMPL-760 will be administered concomitantly with rabeprazole on Day21.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC 0-lastTime frame: Day 1 to Day 25
- AUC 0-infTime frame: Day 1 to Day 25
- CmaxTime frame: Day 1 to Day 25
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Central Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.